

# Strategic alliance between Dedalus and Aiforia to integrate AI into pathology diagnostic workflows for enhanced accuracy and efficiency

Milan, 01 September 2025 – Dedalus Group ("Dedalus"), the European leader in healthcare and diagnostic software solutions, and Aiforia Technologies ("Aiforia"), a pioneer in Al-powered image analysis for pathology, today announced a strategic alliance to bring advanced artificial intelligence capabilities directly into the pathologists' workflow.

This collaboration is designed to enhance diagnostic precision and speed, accelerating turnaround times, and ultimately improving patient outcomes.

The rising global demand for pathology services, driven by increasing cancer incidence and a shortage of qualified pathologists, is compelling laboratories to adopt technologies that improve efficiency, ensure diagnostic precision, and reduce turnaround times.

Dedalus' InVitro AIS Suite addresses these needs by offering interoperability with existing multi-vendor systems and supporting a seamless integration with advanced AI solutions. With over 40 years of experience and a presence in more than 5,700 laboratories worldwide, Dedalus continues to deliver innovative solutions that make laboratory operations more agile, efficient, and accurate.

Through this partnership, Aiforia's advanced AI solutions can be integrated within Dedalus' AIS solutions, reinforcing the central role of the AIS in the diagnostic workflow. This approach is essential for developing robust, efficient, and transformative solutions that elevate current practices. AI results can be made available directly within the pathologists' reports—streamlining reporting, increasing productivity, and improving diagnostic confidence.

"Integrating AI natively into the AIS transforms the diagnostic workflow by combining advanced automation with the pathologist's core environment. This synergy enhances efficiency, improves accuracy, and accelerates decision-making—ultimately driving better outcomes for both laboratories and patients" said Pietro Macri', Portfolio & Engineering Italy and IVD Global Leader at Dedalus.

"Aiforia's long-standing goal has been to leverage AI to enhance the precision and efficiency of pathology diagnostics," said Jukka Tapaninen, CEO of Aiforia. "By integrating our AI solutions into the



Dedalus' InVitro Anatomic Pathology Information System, we are offering pathology laboratories a seamless user experience to incorporate Al-driven insights into their existing workflows. This integration streamlines pathologist's diagnostic work and reporting, making Al an indispensable everyday tool without causing any disruption."

.....

#### **ABOUT DEDALUS**

Dedalus Group is the leading healthcare and diagnostic software provider in Europe, supporting globally the digital transformation of 7500 Healthcare Organisations and 5700 Labs and Diagnostic centres worldwide, processing its solutions for more than 540 million of population worldwide. Dedalus offer supports the whole continuum of care, in every step and phase, offering open standards-based solutions serving each actor of the Healthcare Ecosystem to provide better care in a healthier planet. Life Flows through our software.

For more information, visit www.dedalus.com

#### **ABOUT AIFORIA**

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with an office in Cambridge, Massachusetts, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, Al and software developers, and a dedicated commercial team. Together, they are working to transform pathology with Al, enabling better care for each patient.

For more information, visit www.aiforia.com

### CONTACT

DEDALUS SPA For further information:

Press Contact: Sara Luisa Mintrone www.dedalus.com

Tel number +39 348 2818185 <u>LinkedIn</u>: <u>Dedalus group</u>

sara.mintrone@dedalus.eu

Aiforia Technologies Plc For further information:



Press Contact: Jukka Tapaninen

Tel number: +33 61 041 6686

jukka.tapaninen@aiforia.com

## www.aiforia.com

LinkedIn:

https://www.linkedin.com/company/aiforia-

tech/